148 related articles for article (PubMed ID: 3736880)
21. Chromatic and achromatic visual evoked potentials in Parkinson's disease.
Büttner T; Kuhn W; Müller T; Heinze T; Pühl C; Przuntek H
Electroencephalogr Clin Neurophysiol; 1996 Sep; 100(5):443-7. PubMed ID: 8893662
[TBL] [Abstract][Full Text] [Related]
22. Time course of frontal somatosensory evoked potentials. Relation to L-dopa plasma levels and motor performance in PD.
Ulivelli M; Rossi S; Pasqualetti P; Rossini PM; Ghiglieri O; Passero S; Battistini N
Neurology; 1999 Oct; 53(7):1451-7. PubMed ID: 10534250
[TBL] [Abstract][Full Text] [Related]
23. Response to L-dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease.
Shif M; Kempster PA
Clin Exp Neurol; 1994; 31():38-42. PubMed ID: 7586663
[TBL] [Abstract][Full Text] [Related]
24. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
Lees AJ; Tolosa E; Olanow CW
Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
[TBL] [Abstract][Full Text] [Related]
25. [Event-related potential and visual evoked potential in patients with Parkinson's disease].
Takeda M; Tachibana H; Okuda B; Kawabata K; Sugita M
Nihon Ronen Igakkai Zasshi; 1993 May; 30(5):363-8. PubMed ID: 8331829
[TBL] [Abstract][Full Text] [Related]
26. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
[TBL] [Abstract][Full Text] [Related]
27. Visual evoked cortical responses and electroretinograms following implantation of human fetal mesencephalon to the right caudate nucleus in Parkinson's disease.
Henderson B; Good PA; Hitchcock ER; Clough CG; Hughes RC; Kenny BG
J Neurol Sci; 1992 Feb; 107(2):183-90. PubMed ID: 1564516
[TBL] [Abstract][Full Text] [Related]
28. Prolonged latencies of pattern reversal visual evoked early potentials in Alzheimer disease.
Partanen J; Hartikainen P; Könönen M; Jousmäki V; Soininen H; Riekkinen P
Alzheimer Dis Assoc Disord; 1994; 8(4):250-8. PubMed ID: 7888155
[TBL] [Abstract][Full Text] [Related]
29. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
[TBL] [Abstract][Full Text] [Related]
30. Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test.
Fabbri M; Coelho M; Guedes LC; Chendo I; Sousa C; Rosa MM; Abreu D; Costa N; Godinho C; Antonini A; Ferreira JJ
Parkinsonism Relat Disord; 2017 Jun; 39():37-43. PubMed ID: 28389156
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous VEP and PERG investigations in early Parkinson's disease.
Calzetti S; Franchi A; Taratufolo G; Groppi E
J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):114-7. PubMed ID: 2313297
[TBL] [Abstract][Full Text] [Related]
32. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
Hironishi M; Miwa H; Kondo T
No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
[TBL] [Abstract][Full Text] [Related]
33. [The L-dopa test in Parkinson's disease].
Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y
Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732
[TBL] [Abstract][Full Text] [Related]
34. [The electroretinogram and visual evoked potentials in patients with Parkinson's disease].
Burguera JA; Vilela C; Traba A; Ameave Y; Vallet M
Arch Neurobiol (Madr); 1990; 53(1):1-7. PubMed ID: 2393335
[TBL] [Abstract][Full Text] [Related]
35. Parkinson's dementia and Alzheimer's dementia: an evoked potential comparison.
O'Mahony D; Rowan M; Feely J; O'Neill D; Walsh JB; Coakley D
Gerontology; 1993; 39(4):228-40. PubMed ID: 8244051
[TBL] [Abstract][Full Text] [Related]
36. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
37. Study of central motor functions using magnetic stimulation in Parkinson's disease.
Diószeghy P; Hidasi E; Mechler F
Electromyogr Clin Neurophysiol; 1999 Mar; 39(2):101-5. PubMed ID: 10207679
[TBL] [Abstract][Full Text] [Related]
38. Effects of subthalamic nucleus deep brain stimulation and L-DOPA on blinking in Parkinson's disease.
Bologna M; Fasano A; Modugno N; Fabbrini G; Berardelli A
Exp Neurol; 2012 May; 235(1):265-72. PubMed ID: 22366535
[TBL] [Abstract][Full Text] [Related]
39. Hypotensive effect of long-term levodopa in patients with Parkinson's disease.
Iwasaki S; Hamaguchi K; Iwasaki A; Takakusagi M; Narabayashi Y
Eur Neurol; 1990; 30(4):194-9. PubMed ID: 2209672
[TBL] [Abstract][Full Text] [Related]
40. Absence of relationships between L-dopa plasma levels and therapeutic effect in Parkinson's disease treated with L-dopa.
Algeri S; Ruggieri S; Miranda F; Casacchia M; Morselli PL; Agnoli A
Eur Neurol; 1976; 14(3):219-28. PubMed ID: 1278194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
